All Roll Calls
Yes: 183 • No: 11
IndianaSB 282Second Regular Session 124th General Assembly (2026)SenateWALLET
Compounding drugs; registration of medical spas.
Sponsored By: Ed Charbonneau (Republican)
Became Law
health and provider servicesthe housepublic health
Your PRIA Score
Score Hidden
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
4 provisions identified: 1 benefits, 3 costs, 0 mixed.
Limits and penalties for medical spas
Beginning July 1, 2026, a medical spa may not give health or cosmetic services at a place other than the spa office, except for education or training. Spas must follow state advertising rules; the board can suspend a registration for violations. The board can investigate a responsible practitioner and send proven claims to the practitioner’s licensing board. Licensed workers who break this law can be disciplined under state professional rules. The board also works with other professional boards to align standards.
Medical spas must register and staff safely
Beginning July 1, 2026, the law defines what counts as a medical spa and who may serve as a practitioner. The board creates a public list of registered spas and removes private health details. Starting January 1, 2027, every medical spa must register and list its services, whether it compounds drugs, and name a responsible practitioner with a license and prescriptive authority. That practitioner must have training and be on‑site enough to ensure compliance, and must confirm staff are licensed and trained. Spas must report any serious adverse event to the board within 15 days and include required details. Operating without registration can bring a fine up to $5,000 and the board can require you to register.
Stricter rules for drug compounding
Beginning July 1, 2026, you may compound with a bulk drug substance only if key rules are met. The substance cannot be research grade (unless in an IRB‑approved study) or veterinary grade, must be made by an FDA‑registered human drug establishment, must have a valid certificate of analysis, and must pass quality control testing. Compounding must follow the federal Food, Drug, and Cosmetic Act and any applicable USP chapters. Sellers and distributors must keep acquisition, exam, and testing records for at least two years after the last lot’s expiration. Out‑of‑state pharmacies shipping compounded drugs into Indiana must give compliance documents to the board on request. Entities must also follow the federal 503A/503B rules and, when required, new drug approval and cGMP standards.
More state oversight of compounding
Beginning July 1, 2026, the board of pharmacy can investigate sourcing, storage, labeling, handling, and compounding of prescription drugs and any violations. The state must publish oversight reports by March 1 and September 1 each year with license and facility counts, violations, investigations, and discipline, and post them online. The law defines “bulk drug substance” and “compounding” to set clear rules. These compounding rules do not apply to drugs made for animals.
Sponsors & Cosponsors
Sponsor
Ed Charbonneau
Republican • Senate
Cosponsors
Brad Barrett
Republican • House
Chris Judy
Republican • House
Gregory Porter
Democratic • House
Julie McGuire
Republican • House
Justin Busch
Republican • Senate
Roll Call Votes
Senate vote • 2/26/2026
Roll Call 302 on SB0282.05.ENGH.CON01
Yes: 43 • No: 6 • Other: 1
House vote • 2/24/2026
Roll Call 357 on SB0282.04.COMH
Yes: 93 • No: 4 • Other: 2
Senate vote • 1/29/2026
Roll Call 143 on SB0282.02.COMS
Yes: 47 • No: 1
Actions Timeline
Public Law 136
3/5/2026SenateSigned by the Governor
3/5/2026SenateSigned by the President Pro Tempore
2/27/2026SenateSigned by the President of the Senate
2/27/2026SenateSigned by the Speaker
2/27/2026HouseSenate concurred with House amendments; Roll Call 302: yeas 43, nays 6
2/26/2026SenateReturned to the Senate with amendments
2/25/2026HouseMotion to concur filed
2/25/2026SenateThird reading: passed; Roll Call 357: yeas 93, nays 4
2/24/2026HouseRepresentative Judy added as cosponsor
2/24/2026HouseAmendment #1 (Barrett) prevailed; voice vote
2/23/2026HouseSecond reading: amended, ordered engrossed
2/23/2026HouseCommittee report: amend do pass, adopted
2/19/2026HouseRepresentative Porter added as cosponsor
2/12/2026HouseFirst reading: referred to Committee on Public Health
2/2/2026HouseRepresentative McGuire added as cosponsor
1/29/2026HouseReferred to the House
1/29/2026SenateThird reading: passed; Roll Call 143: yeas 47, nays 1
1/29/2026SenateHouse sponsor: Representative Barrett
1/29/2026SenateAmendment #5 (Johnson T) prevailed; voice vote
1/28/2026SenateSecond reading: amended, ordered engrossed
1/28/2026SenateCommittee report: amend do pass, adopted
1/22/2026SenateSenator Busch added as second author
1/12/2026SenateAuthored by Senator Charbonneau
1/12/2026SenateFirst reading: referred to Committee on Health and Provider Services
1/12/2026Senate
Bill Text
Engrossed Senate Bill (H)
Engrossed Senate Bill (S)
Enrolled Senate Bill (S)
Introduced Senate Bill (S)
Senate Bill (H)
Senate Bill (S)